Protagonist Therapeutics, Inc. ist eine Aktie aus dem Premium-Bereich von aktien.guide. Bitte anmelden, um einen Alarm für Protagonist Therapeutics, Inc. zu aktivieren.
Kostenlos registrieren
Bitte registriere Dich kostenlos, um Protagonist Therapeutics, Inc. zu Deinem Portfolio hinzuzufügen.
NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open label extension study will be the focus of an oral presentation at the European Hematology Association (EHA) Congress being held in Madrid, Spain from June 13-16, 2024. There will also be a published a...
NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D.
Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027[1] Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2113 in patients with moderate to severe psoriasis is now complete Data from the Phase 2b FRONTIER 2, a 52-week long term extension study of JNJ-2113 presented at the American Academy of Dermatology...
On track to achieve 250 patient enrollment target in March 2024 Top-line data for 32-week primary endpoint expected in the first quarter of 2025 NEWARK, CA / ACCESSWIRE / March 26, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced it has randomized 241 patients in the ongoing Phase 3 VERIFY clinical trial evaluating rusfertide in polycythemia vera ("PV") as of tod...
NEWARK, CA / ACCESSWIRE / March 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announces the closing of the worldwide collaboration and license agreement for rusfertide with Takeda, a leading values-based, R&D-driven biopharmaceutical company, disclosed on January 31, 2024. Closing of the transaction was contingent on completion of review under the Hart-Scott-R...
NEWARK, CA / ACCESSWIRE / March 6, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that they will participate in three upcoming investor conferences: Event: 2024 Jefferies Biotech on the Bay Summit Date: March 12-13, 2024Location: W Hotel South Beach, Miami, FL. Event: 13th Annual Napa Valley Biotech Forum Date: March 26-28, 2024Presentation: Tuesday, Marc...
Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications Cash runway extended through Q4 2027[1] Two articles published in the New England Journal of Medicine reporting results from the Phase 2b FRONTIER 1 study of JNJ-2113 and the Phase 2 REVIVE study of rusfertide Ou...
- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy - Rusfertide was associated with lower disease-related symptoms in patients with moderate/severe scores at baseline as assessed by the Myeloproliferative Neoplasm Symptom Assessment Form - REVIVE is one of two pivotal studies, inc...
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.